The impact of changes in national prescribing conditions for statins on their public expenditure and utilization in the Czech Republic 1997–2013

Leos Fuksa, Milan Vocelka and Magda Vytrisalova

Health Policy, 2015, vol. 119, issue 9, 1255-1264

Abstract: In the Czech Republic (CZ) extensive price regulation and prescribing conditions are common instruments often employed with new drugs. Since the introduction of statins onto the market in 1990s the originally strict conditions gradually relaxed while the prescription rates and public costs were rising. The aim was to analyze long-term utilization trends of statins, changes in their reimbursement prices and prescribing conditions, and the evolution of the market.

Keywords: Drug utilization; Drug pricing; Health insurance reimbursement; Treatment costs; Statins; HMG-CoA reductase inhibitors (search for similar items in EconPapers)
Date: 2015
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0168851015000676
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:119:y:2015:i:9:p:1255-1264

DOI: 10.1016/j.healthpol.2015.02.016

Access Statistics for this article

Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput

More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu () and ().